Cas:220801-66-1 Methyl 2-(5-bromo-2-hydroxyphenyl)acetate manufacturer & supplier

Chemical Name:Methyl 2-(5-bromo-2-hydroxyphenyl)acetate

CAS.NO:220801-66-1

Synonyms:Methyl 2-(5-bromo-2-hydroxyphenyl)acetate

Molecular Formula:C₉H₉BrO₃

Molecular Weight:245.07000

HS Code:2918290000

Physical and Chemical Properties:

Melting point:N/A

Boiling point:317.143ºC at 760 mmHg

Density:1.562g/cm3

Index of Refraction:1.574

PSA:46.53000

Exact Mass:243.97400

LogP:1.87020

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Methyl 2-(5-bromo-2-hydroxyphenyl)acetate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Methyl 2-(5-bromo-2-hydroxyphenyl)acetate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Methyl 2-(5-bromo-2-hydroxyphenyl)acetate Use and application,Methyl 2-(5-bromo-2-hydroxyphenyl)acetate technical grade,usp/ep/jp grade.

Related News: The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years. Methyl 2-(5-bromo-2-hydroxyphenyl)acetate manufacturer At present, Linhai, Zhejiang Province, has established a national chemical raw material base in Zhejiang Province, which is the earliest and largest gathering area of ??domestic chemical raw material medicines and pharmaceutical intermediate industries. Methyl 2-(5-bromo-2-hydroxyphenyl)acetate supplier ��We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,�� said Ed Damiano, President and CEO of Beta Bionics. ��We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.�� Methyl 2-(5-bromo-2-hydroxyphenyl)acetate vendor The two trials studied similar patient populations, Tendler said, but VMP was an old standard of care that’s not really used today in the U.S. Still, Tendler believes the two regimens may both have roles to play based on each patient’s ability to tolerate them. Whichever cocktail physicians choose, the two phase 3 studies have confirmed the benefit of Darzalex in transplant-ineligible patients, he added. Methyl 2-(5-bromo-2-hydroxyphenyl)acetate factory The two trials studied similar patient populations, Tendler said, but VMP was an old standard of care that’s not really used today in the U.S. Still, Tendler believes the two regimens may both have roles to play based on each patient’s ability to tolerate them. Whichever cocktail physicians choose, the two phase 3 studies have confirmed the benefit of Darzalex in transplant-ineligible patients, he added.